Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infection

A. K.A. Wright; D. E. Briles; D. W. Metzger; Stephen Gordon

doi:10.1016/j.vaccine.2008.06.058

Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infection

A. K.A. Wright
, D. E. Briles
, D. W. Metzger
, Stephen Gordon

Clinical Sciences

Liverpool University Hospitals NHS Foundation Trust
Liverpool School of Tropical Medicine
University of Alabama at Birmingham
Albany Medical College

Research output: Contribution to journal › Review article › peer-review

24 Citations (Scopus)

Abstract

Mucosal vaccination against pneumococcal disease offers potential protection against otitis media, pneumonia and invasive disease, including providing herd benefit by reducing pathogen carriage. The major obstacle, however, remains the lack of a suitable adjuvant for use in humans. Animal models have demonstrated success of interleukin-12 (IL-12) as an adjuvant for mucosal vaccines using recombinant pneumococcal protein antigens.

This review examines the biology of the IL-12 cytokine family, the toxicity of IL-12 in human studies and suggests approaches by which IL-2 could be developed as a mucosal adjuvant with pneumococcal protein based vaccines, for use in humans. (C) 2008 Published by Elsevier Ltd.

Original language	English
Pages (from-to)	4893-4903
Number of pages	11
Journal	Vaccine
Volume	26
Issue number	38
DOIs	https://doi.org/10.1016/j.vaccine.2008.06.058
Publication status	Published - 8 Sept 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Lung
Mucosal vaccine
Streptococcus pneumoniae

Access to Document

10.1016/j.vaccine.2008.06.058

Cite this

@article{14935ac98d5148be81010e2c68598578,

title = "Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infection",

abstract = "Mucosal vaccination against pneumococcal disease offers potential protection against otitis media, pneumonia and invasive disease, including providing herd benefit by reducing pathogen carriage. The major obstacle, however, remains the lack of a suitable adjuvant for use in humans. Animal models have demonstrated success of interleukin-12 (IL-12) as an adjuvant for mucosal vaccines using recombinant pneumococcal protein antigens.This review examines the biology of the IL-12 cytokine family, the toxicity of IL-12 in human studies and suggests approaches by which IL-2 could be developed as a mucosal adjuvant with pneumococcal protein based vaccines, for use in humans. (C) 2008 Published by Elsevier Ltd.",

keywords = "Lung, Mucosal vaccine, Streptococcus pneumoniae",

author = "Wright, \{A. K.A.\} and Briles, \{D. E.\} and Metzger, \{D. W.\} and Stephen Gordon",

year = "2008",

month = sep,

day = "8",

doi = "10.1016/j.vaccine.2008.06.058",

language = "English",

volume = "26",

pages = "4893--4903",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "38",

}

TY - JOUR

T1 - Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infection

AU - Wright, A. K.A.

AU - Briles, D. E.

AU - Metzger, D. W.

AU - Gordon, Stephen

PY - 2008/9/8

Y1 - 2008/9/8

N2 - Mucosal vaccination against pneumococcal disease offers potential protection against otitis media, pneumonia and invasive disease, including providing herd benefit by reducing pathogen carriage. The major obstacle, however, remains the lack of a suitable adjuvant for use in humans. Animal models have demonstrated success of interleukin-12 (IL-12) as an adjuvant for mucosal vaccines using recombinant pneumococcal protein antigens.This review examines the biology of the IL-12 cytokine family, the toxicity of IL-12 in human studies and suggests approaches by which IL-2 could be developed as a mucosal adjuvant with pneumococcal protein based vaccines, for use in humans. (C) 2008 Published by Elsevier Ltd.

AB - Mucosal vaccination against pneumococcal disease offers potential protection against otitis media, pneumonia and invasive disease, including providing herd benefit by reducing pathogen carriage. The major obstacle, however, remains the lack of a suitable adjuvant for use in humans. Animal models have demonstrated success of interleukin-12 (IL-12) as an adjuvant for mucosal vaccines using recombinant pneumococcal protein antigens.This review examines the biology of the IL-12 cytokine family, the toxicity of IL-12 in human studies and suggests approaches by which IL-2 could be developed as a mucosal adjuvant with pneumococcal protein based vaccines, for use in humans. (C) 2008 Published by Elsevier Ltd.

KW - Lung

KW - Mucosal vaccine

KW - Streptococcus pneumoniae

U2 - 10.1016/j.vaccine.2008.06.058

DO - 10.1016/j.vaccine.2008.06.058

M3 - Review article

SN - 0264-410X

VL - 26

SP - 4893

EP - 4903

JO - Vaccine

JF - Vaccine

IS - 38

ER -

Prospects for use of interleukin-12 as a mucosal adjuvant for vaccination of humans to protect against respiratory pneumococcal infection

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this